Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VYNE Therapeutics Inc.    VYNE

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales1 3,673,600,4421,961,9121
EBITDA -65,4-74,6----
Operating profit (EBIT)1 -65,6-74,9-95,9-190-65,5-15,9
Operating Margin -1 788%-2 083%-21 642%-866%-106%-13,1%
Pre-Tax Profit (EBT)1 -64,6-74,0-95,4-258-79,1-30,9
Net income1 -65,7-74,2-95,2-258-79,1-30,9
Net margin -1 791%-2 063%-21 485%-1 179%-128%-25,6%
EPS2 ----2,29-0,42-0,18
Dividend per Share ------
Last update 02/27/201802/28/201903/12/2020---
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt ------
Net Cash position ------
Leverage (Debt / EBITDA) ------
Free Cash Flow1 -54,7-69,2-74,5-111-68,5-15,9
ROE (Net Profit / Equities) -66,2%-92,3%----
Shareholders' equity1 99,380,4----
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share ------
Cash Flow per Share ------
Capex1 1,520,571,064,204,204,20
Capex / Sales 41,4%15,8%239%19,2%6,78%3,47%
Last update 02/27/201802/28/201903/12/202011/06/202012/16/202012/16/2020
1 USD in Million
Estimates
Finances - Leverage
Financial data source
© 2021 S&P Global Market Intelligence